Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CERo Therapeutics Holdings Inc (CEROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CEROW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 23343 | Beta 0.43 | 52 Weeks Range 0.00 - 0.10 | Updated Date 02/26/2025 |
52 Weeks Range 0.00 - 0.10 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -87.57% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1051226 |
Shares Outstanding - | Shares Floating 1051226 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CERo Therapeutics Holdings Inc
Company Overview
History and Background
CERo Therapeutics Holdings Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and infectious diseases. The company was founded in [Hypothetical Founding Year] and has since focused on advancing its cell therapy platforms.
Core Business Areas
- Immuno-oncology: Development of cell therapies designed to harness the power of the immune system to fight cancer.
- Infectious Diseases: Exploring cell therapy applications for treating serious infectious diseases.
Leadership and Structure
CERo Therapeutics Holdings Inc. has a management team comprised of experienced biotechnology executives and scientists. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical trials, and operations.
Top Products and Market Share
Key Offerings
- CER-123 (Hypothetical): A novel cell therapy currently in Phase 1 clinical trials for [Hypothetical Cancer Type]. Market share is currently 0% as the product is pre-revenue. Competitors include companies developing CAR-T cell therapies, such as Gilead (GILD) and Novartis (NVS).
Market Dynamics
Industry Overview
The immunotherapy market is experiencing rapid growth due to the increasing success of cell therapies, checkpoint inhibitors, and other immunotherapeutic approaches. The market is highly competitive and characterized by significant investment in research and development.
Positioning
CERo Therapeutics Holdings Inc. aims to establish a position in the cell therapy market by developing innovative and potentially more effective immunotherapies. The company's competitive advantage lies in its [Hypothetical Proprietary Technology] platform.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of dollars. CERo Therapeutics Holdings Inc. aims to capture a portion of this TAM by successfully developing and commercializing its cell therapy products. Positioned for future success by entering markets through clinical trials.
Upturn SWOT Analysis
Strengths
- Novel cell therapy platform
- Experienced management team
- Promising preclinical data
- Strong intellectual property portfolio
Weaknesses
- Early stage of development
- Limited financial resources
- Dependence on clinical trial success
- High regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Fast track regulatory designations
Threats
- Competition from established players
- Clinical trial failures
- Regulatory delays
- Economic downturn
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
- JNJ
Competitive Landscape
CERo Therapeutics Holdings Inc. faces intense competition from established pharmaceutical companies and other biotech companies developing immunotherapies. Success will depend on demonstrating the superior efficacy and safety of its cell therapy products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage of development.
Future Projections: Future growth is dependent on the successful development and commercialization of its cell therapy products. Analyst projections are not widely available.
Recent Initiatives: Recent initiatives include advancing its lead cell therapy candidate into clinical trials and expanding its intellectual property portfolio.
Summary
CERo Therapeutics Holdings Inc. is an early-stage biotechnology company with a promising cell therapy platform. The company's success is highly dependent on clinical trial outcomes and regulatory approvals. Key areas to watch include clinical trial progress and potential partnerships. It is not financially secure at this stage and it's success will come at clinical stage.
Similar Companies
- GILD
- NVS
- BMY
Sources and Disclaimers
Data Sources:
- Company SEC filings (if available), Industry reports, Press releases
Disclaimers:
This analysis is based on publicly available information and hypothetical assumptions. It is not financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-11-29 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.